Latest Hepacivac Stories
Nature Communications paper offers pivotal new information about how the virus interacts with and evades therapeutics, as well as new clues to its role in cancer development. New
- Interim Results from Ongoing Study Demonstrate Human Proof-of-Concept and Underscore the Value of Regulus' microRNA Platform - LA JOLLA, Calif., Oct.
- Results Confirm Efficacy and Safety of an All-Oral combination of Mogrovir(TM) with Ribavirin(TM) in Genotype 1, Therapy Naive HCV Patients. LOS ANGELES, July 1, 2014 /PRNewswire/
Arrival of IFN-Free Therapies Will Bring Patients For Whom Current Therapies are Ineffective Back to the Drug-Treated Population, According to Findings from Decision Resources Group BURLINGTON,
SYDNEY, May 29, 2014 /PRNewswire/ -- RNAi-based therapeutics company, Benitec Biopharma Limited (ASX: BLT) is pleased to announce that it has dosed the first patient in its 'first in man', Phase I/IIa
To the relief of patients diagnosed with hepatitis C, the U.S. Food and Drug Administration approved two new treatments late last year, and a few more are on the way.
People who inject drugs and are enrolled in a drug treatment program are receptive to education about, and treatment for, hepatitis C virus.
-Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date(1) NORTH CHICAGO, Ill., April 22, 2014 /PRNewswire/ -- AbbVie (NYSE:
NEW YORK, March 25, 2014 /PRNewswire/ -- At the New York Viral Hepatitis Summit presented by the National Black Leadership Commission
Additional drug-drug interaction data for faldaprevir combined with commonly prescribed HIV medications also presented at CROI 2014 INGELHEIM, Germany and RIDGEFIELD, Conn., March
- A transitional zone between two communities containing the characteristic species of each.